Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial

Diseases of the Esophagus

Volumn 29, Issue 8, 2016, Pages 1152-1158

  Horgan, A M ^a,e   Darling, G ^a   Wong, R ^a   Guindi, M ^d   Liu, G ^a   Jonker, D J ^b   Lister, J ^a   Xu, W ^a   MacKay, H M ^a   Dinniwell, R ^a   Kim, J ^a   Pierre, A ^a   Shargall, Y ^c   Asmis, T R ^b   Agboola, O ^b   Seely, A J ^b   Ringash, J ^a   Wells, J ^b   Marginean, E C ^b   Haider, M ^a   Knox, J J ^a   more..

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e WATERFORD REGIONAL HOSPITAL   (Ireland)

Author keywords

esophageal cancer; sunitinib; trimodality

Indexed keywords

CISPLATIN; IRINOTECAN; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; FATIGUE; FEASIBILITY STUDY; FEMALE; FLATULENCE; GASTROESOPHAGEAL JUNCTION; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEARTBURN; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; PAIN; PERFORATION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE FRACTIONATION; RASH; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; POSTOPERATIVE PERIOD; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEASIBILITY STUDIES; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PYRROLES; SURVIVAL RATE; WITHHOLDING TREATMENT;

EID: 84983159926     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12444     Document Type: Article

References (27)

1. Visbal A L, Allen M S, Miller D L et al. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001; 71: 1803–1808.
2. Greer S E, Goodney P P, Sutton J E et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005; 137: 172–177.
3. Kitadai Y, Haruma K, Tokutomi T et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998; 4: 2195–2200.
4. Inoue K, Ozeki Y, Suganuma T et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79: 206–213.
5. Shih C H, Ozawa S, Ando N et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000; 6: 1161–1168.
6. Li Z, Shimada Y, Uchida S et al. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000; 17: 453–460.
7. Kleespies A, Guba M, Jauch K W et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87: 95–104.
8. Zhu A X, Willett C G. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin Radiat Oncol 2003; 13: 454–468.
9. O'Farrell A M, Abrams T J, Yuen H A et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–3605.
10. Raymond E, Dahan L, Raoul J L et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501–513.
11. Demetri G D, van Oosterom A T, Garrett C R et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329–1338.
12. Motzer R J, Hutson T E, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–124.
13. Knox J J, Wong R, Visbal A L et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer 2010; 116: 4023–4032.
14. Mandard A M, Dalibard F, Mandard J C et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–2686.
15. Therasse P, Arbuck S G, Eisenhauer E A et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216.
16. Ferrara N G H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.
17. Mobius C, Stein H J, Becker I et al. The ‘angiogenic switch’ in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003; 29: 890–894.
18. Maeda K, Chung Y S, Ogawa Y et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858–863.
19. Bang Y J, Kang Y K, Kang W K et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011; 29: 1449–1458.
20. Moehler M, Mueller A, Hartmann J T et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011; 47: 1511–1520.
21. Schmitt J M, Sommers S R, Fisher W et al. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol 2012; 7: 760–763.
22. Yi J H, Lee J, Lee J et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012; 106: 1469–1474.
23. Sun W, Powell M, O'Dwyer P J et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28: 2947–2951.
24. Ilson D J Y, Shah M A, Kelsen D P et al. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: response and protracted stable disease observed in adenocarcinoma. J Clin Oncol 2011; 29 (Suppl. abstr 4100).
25. Ilson D H, Bains M, Kelsen D P et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003; 21: 2926–2932.
26. Willett C G, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145–147.
27. Ilson D G K, Janjigian Y Y, Shah M A et al. Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma. J Clin Oncol 2012; 30 (Suppl 4).